The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Apixaban (Eliquis®) has been accepted for use in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE in adults.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« Pregabalin Prescribing Guidance||Creon 40,000 temporarily unavailable »|